Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Galapagos NV
GLPG | US
28.60
USD-0.08
-0.28%
GLPG | US
About Galapagos NV
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
28.60
Open
28.81
High
28.81
Low
28.30
Galapagos NV an integrated biopharmaceutical company engages in the discovery development and commercialization of"various medicines for high unmet medical need. Its pipeline products include filgotinib a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis Crohn's disease ulcerative colitis ankylosing spondylitis psoriatic arthritis and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201 CD19 CAR-T product candidate manufactures at point-of-care that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences Inc.; AbbVie S.Ã r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen Belgium."
View LessGLPG | US
Risk
26.2
Sharpe
0.24
Luna's Score
54/100
Recommendation
Hold
Luna says (GLPG | US)
What's Working
Low 6-Month Volatility (<30%)
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
16.5%1 month
26.2%3 months
27.4%6 months
25.5%Returns
Fundamental Ratios
PE
59.15
Fwd. PE
166.67
Price to book
0.63
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-31.50
Ent. to rev.
1.18
PEG
-
Other Fundamentals
EBITDA
-101.32M
MarketCap
1.88B
MarketCap(USD)
1.88B
Div. yield
-
Op. margin
-49.03
Erngs. growth
74.80
Rev. growth
29.70
Ret. on equity
1.15
Short ratio
12.43
Short perc.
3.08
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.47
Range1M
2.88
Range3M
8.27
Volumes: Market Activity
Rel. volume
0.57
Price X volume
2.93M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -31.50 | - | Cheaper |
| Ent. to Revenue | 1.18 | - | Cheaper |
| PE Ratio | 59.15 | 41.03 | Expensive |
| Price to Book | 0.63 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 27.37 | - | Lower Risk |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 1.88B | - | Emerging |
